Huntington Ingalls, Crocs, Carvana, Insmed And Other Big Stocks Moving Higher On Thursday
Stocks rallied on strong earnings and raised guidance, led by Huntington Ingalls, Porch, Teladoc and Crocs, despite the Dow falling 150 points.
Stocks · News reference
Bausch Health's Salix Pharmaceuticals to Present New Data at The Liver Meeting 2026
Bausch Health and its Salix Pharmaceuticals division will present research on cirrhosis trends and severe alcohol-associated hepatitis at the American Association for the Study of Liver Diseases' The Liver Meeting 2026.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
RBC Raises Price Target on Bausch Health to $10 From $9
RBC has increased its price target for Bausch Health Companies Inc. to $10 from $9 while maintaining a Sector Perform rating.
Bausch Health Announces Third Quarter 2026 Financial Results and Raises Guidance
Bausch Health reported strong third-quarter 2026 financial results, including a 10% increase in consolidated revenues and an increase in adjusted earnings per share, leading the company to raise its financial guidance.
Bausch Health Announces Full Redemption of 8.500% Senior Notes Due 2027
Bausch Health plans to redeem approximately $643 million of its outstanding 8.500% senior notes due in 2027 using cash on hand.
Bausch Health Authorizes $50 Million Share Repurchase Program
Bausch Health has authorized a new share repurchase program to buy back up to $50 million of its common shares to offset potential dilution from employee equity compensation.
8-K filing — Bausch Health Companies Inc. (BHC)
Filed: 2026-10-28 AccNo: 0000885590-26-000121 Size: 1 MB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits